Spots Global Cancer Trial Database for ovarian cancer recurrent
Every month we try and update this database with for ovarian cancer recurrent cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer | NCT04175470 | Ovarian Cancer ... | Bevacizumab Tocotrienol | 18 Years - | Vejle Hospital | |
| Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer | NCT04072263 | Ovarian Cancer ... | Tumor Infiltrat... Interferon Alfa... Carboplatin Paclitaxel | 18 Years - | Leiden University Medical Center | |
| Microtransplantation for Ovarian Cancer | NCT05095558 | Ovarian Cancer ... | microtransplant... | 18 Years - 80 Years | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy | NCT05990192 | Ovarian Cancer ... | Niraparib oral ... SBRT | 18 Years - | Institute of Cancer Research, United Kingdom | |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | NCT03162562 | Cancer of Ovary Neoplasms, Ovar... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovary Cancer | Oregovomab Poly ICLC | 18 Years - 90 Years | CanariaBio Inc. | |
| SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy | NCT05990192 | Ovarian Cancer ... | Niraparib oral ... SBRT | 18 Years - | Institute of Cancer Research, United Kingdom | |
| IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer | NCT06014528 | Ovarian Cancer ... | IN10018 Placebo of IN10... Pegylated Lipos... | 18 Years - | InxMed (Shanghai) Co., Ltd. | |
| The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients | NCT06102707 | Ovarian Cancer ... | Fluzopril Combi... | 18 Years - | Qilu Hospital of Shandong University | |
| EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer | NCT01485848 | Ovarian Cancer ... | EP-100 Paclitaxel | 18 Years - | Esperance Pharmaceuticals Inc | |
| IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer | NCT06014528 | Ovarian Cancer ... | IN10018 Placebo of IN10... Pegylated Lipos... | 18 Years - | InxMed (Shanghai) Co., Ltd. | |
| Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer | NCT03734692 | Ovarian Cancer ... | Rintatolimod Pembrolizumab Cisplatin | 18 Years - | University of Pittsburgh | |
| Microtransplantation for Ovarian Cancer | NCT05095558 | Ovarian Cancer ... | microtransplant... | 18 Years - 80 Years | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel | NCT01332656 | Ovarian Cancer ... | Ombrabulin (AVE... Placebo Paclitaxel Carboplatin | 18 Years - | Sanofi | |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | NCT03162562 | Cancer of Ovary Neoplasms, Ovar... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovary Cancer | Oregovomab Poly ICLC | 18 Years - 90 Years | CanariaBio Inc. | |
| Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer | NCT03734692 | Ovarian Cancer ... | Rintatolimod Pembrolizumab Cisplatin | 18 Years - | University of Pittsburgh | |
| Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer | NCT04149145 | Ovarian Cancer ... | M4344+Niraparib M4344+Niraparib | 18 Years - | University of Alabama at Birmingham | |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | NCT05001282 | Ovarian Cancer Ovarian Neoplas... Ovarian Carcino... Endometrial Can... Ovary Cancer Ovary Neoplasm Ovary Disease Ovary Metastasi... Ovarian Disease... Ovarian Cancer ... Ovarian Epithel... Ovarian Adenoca... Ovarian Serous ... Ovarian Neoplas... Ovarian Cancer ... Endometrial Dis... Endometrial Ade... Endometrial Car... Endometrial Cle... Endometrioid Ad... Endometrial Neo... Endometrial Can... Endometrioid Tu... Fallopian Tube ... Peritoneal Canc... | ELU001 | 18 Years - | Elucida Oncology | |
| A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer. | NCT03681548 | Ovarian Cancer ... | Doxorubicin Hyd... | 18 Years - 65 Years | Ayana Pharma Ltd., | |
| A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse | NCT01111903 | Ovarian Cancer ... | Lenalidomide | 18 Years - | ARCAGY/ GINECO GROUP | |
| Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors | NCT03827837 | Renal Cell Carc... Urothelial Carc... Cervical Cancer Ovarian Cancer ... Endometrial Can... | SHR-1210 Famitinib | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer | NCT04175470 | Ovarian Cancer ... | Bevacizumab Tocotrienol | 18 Years - | Vejle Hospital | |
| Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer | NCT04175470 | Ovarian Cancer ... | Bevacizumab Tocotrienol | 18 Years - | Vejle Hospital | |
| Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer | NCT04149145 | Ovarian Cancer ... | M4344+Niraparib M4344+Niraparib | 18 Years - | University of Alabama at Birmingham | |
| Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) | NCT03983226 | Ovarian Cancer ... Fallopian Tube ... Primary Periton... | Surgery carboplatin/tax... Niraparib | 18 Years - 75 Years | Shanghai Gynecologic Oncology Group | |
| Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer | NCT03717610 | Ovarian Cancer ... | radical surgery... | 18 Years - 70 Years | Uppsala University Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
